Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?

The first preplanned interim PFS analysis, after a median follow up of 14.5 months, showed a highly significant difference in median PFS in favor of consolidation therapy with durvalumab, with a clinically relevant improvement in PFS from 16.8 versus 5.6 months from randomization (HR 0.52) ( Figure 3 ).

also in 132,142 other papers